Acumen, Lonza Extend Deal to Add Manufacturing of Sabirnetug for Alzheimer's Disease

MT Newswires Live09-26

Acumen Pharmaceuticals (ABOS) said Thursday that it has extended its partnership with Lonza to offer drug product manufacturing for clinical and potential commercial supply from the latter's Visp, Switzerland, facility to treat Alzheimer's disease.

The extended agreement requires Lonza to produce cGMP drug product of sabirnetug for the current and future clinical studies and also provide quality control and stability testing, Acumen said.

Financial details of the partnership were not disclosed.

The companies first signed a collaboration deal in April.

Shares of the company were up 5% in recent Thursday premarket activity.

Price: 2.4600, Change: +0.12, Percent Change: +5.13

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2470092735?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-26 20:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470092735","market":"nz","top_or_hot":-1,"title":"Acumen, Lonza Extend Deal to Add Manufacturing of Sabirnetug for Alzheimer's Disease","media":"MT Newswires Live","content":"<html><body><p> Acumen Pharmaceuticals (ABOS) said Thursday that it has extended its partnership with Lonza to offer drug product manufacturing for clinical and potential commercial supply from the latter's Visp, Switzerland, facility to treat Alzheimer's disease.</p><p>The extended agreement requires Lonza to produce cGMP drug product of sabirnetug for the current and future clinical studies and also provide quality control and stability testing, Acumen said.</p><p>Financial details of the partnership were not disclosed.</p><p>The companies first signed a collaboration deal in April.</p><p>Shares of the company were up 5% in recent Thursday premarket activity.</p><p>Price: 2.4600, Change: +0.12, Percent Change: +5.13</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acumen, Lonza Extend Deal to Add Manufacturing of Sabirnetug for Alzheimer's Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcumen, Lonza Extend Deal to Add Manufacturing of Sabirnetug for Alzheimer's Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-26 20:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Acumen Pharmaceuticals (ABOS) said Thursday that it has extended its partnership with Lonza to offer drug product manufacturing for clinical and potential commercial supply from the latter's Visp, ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2470092735","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470092735","pubTimestamp":1727355520,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Acumen Pharmaceuticals  said Thursday that it has extended its partnership with Lonza to offer drug product manufacturing for clinical and potential commercial supply from the latter's Visp, Switzerland, facility to treat Alzheimer's disease.The extended agreement requires Lonza to produce cGMP drug product of sabirnetug for the current and future clinical studies and also provide quality control and stability testing, Acumen said.Financial details of the partnership were not disclosed.The companies first signed a collaboration deal in April.Shares of the company were up 5% in recent Thursday premarket activity.Price: 2.4600, Change: +0.12, Percent Change: +5.13","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","ABOS":"Acumen Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Acumen与Lonza延长协议，增加治疗阿尔茨海默病的Sabirnetug的生产","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABOS":0.9},"content_text":"Acumen Pharmaceuticals (ABOS) said Thursday that it has extended its partnership with Lonza to offer drug product manufacturing for clinical and potential commercial supply from the latter's Visp, Switzerland, facility to treat Alzheimer's disease.The extended agreement requires Lonza to produce cGMP drug product of sabirnetug for the current and future clinical studies and also provide quality control and stability testing, Acumen said.Financial details of the partnership were not disclosed.The companies first signed a collaboration deal in April.Shares of the company were up 5% in recent Thursday premarket activity.Price: 2.4600, Change: +0.12, Percent Change: +5.13","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470092735"}